BioNTech SE · NASDAQ:BNTX
BioNTech — Q1 2026 Earnings Presentation
27 slides from BioNTech's earnings presentation, May 5, 2026
Slide 1: First Quarter 2026 Financial Results & Corporate Update
First Quarter 2026 Financial Results & Corporate Update May 5, 2026
Slide 2: This Slide Presentation Includes Forward-Looking Statements
To be updated by Legal This Slide Presentation Includes Forward-Looking Statements This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, but not limited to, statements concerning: BioNTech’s expected r
Slide 3: Progress Highlights, Oncology Execution, Financial Performance
1 Progress Highlights Prof. Uğur Şahin, M.D., Co-Founder & Chief Executive Officer 2 Oncology Execution Prof. Özlem Türeci, M.D., Co-Founder & Chief Medical Officer 3 Financial Performance Ramón Zapata, Chief Financial Officer
Slide 4: Progress Highlights
1 Progress Highlights Prof. Uğur Şahin, M.D., Co-Founder & Chief Executive Officer 4
Slide 5: Oncology Focus in 2026
Oncology 1 Late-Stage Acceleration Key late-stage data readouts expected for first wave of oncology assets Focus in 2026 2 Combination Therapy Momentum Novel-novel pumitamig1 combination data readouts expected 3 Modalities to Disease Areas Transition to a focused disease area specific approach 1. Pa
Slide 6: Building a Multi-Product Company by 2030
Building a Multi-Product Company by 2030 Targeting 17+ Late-Stage/Pivotal Trial Readouts Through 2030+ Informing Multiple Launch Opportunities Expected Data Readouts2 Tumor Type Incidence1 Assets Late-Stage/Pivotal Trials 2026 2027 2028 2029 2030+ 1L NSCLC 400K Pumitamig3 ROSETTA Lung-02 Stage III u
Slide 7: Oncology Execution
2 Oncology Execution Prof. Özlem Türeci, M.D., Co-Founder & Chief Medical Officer 7
Slide 8: BioNTech Key Tumor Focus Areas to Address Significant Unmet Medical Needs
BioNTech Key Tumor Focus Areas to Address Significant Unmet Medical Needs ADC Pumitamig1 IO mRNA Lung Breast Genitourinary Gastrointestinal Gynecologic Additional Tumors Leveraging novel combinations to maximize pipeline potential and elevate solid tumor treatment outcomes 1. Partnered with Bristol
Slide 9: Broadening BioNTech's Coverage of Lung Cancer to Maximize Pipeline Potential
Broadening BioNTech’s Coverage of Lung Cancer to Maximize Pipeline Potential NSCLC SCLC Stage III Resectable 1L metastatic 2L+ metastatic 1L metastatic 2L+ metastatic Unresectable Incidence1 220K 65K 400K 230K 80K 35K Pumitamig2 Gotistobart3 ROSETTA PRESERVE-003 Pumitamig2 + LUNG-202 (sq) Pumitamig2
Slide 10: Pumitamig Data Show Preliminary Antitumor Activity Irrespective of PD-L1 Expression in NSCLC
Pumitamig Data Show Preliminary Antitumor Activity Irrespective of PD-L1 Expression in NSCLC Phase 1/2 Trial in China Monotherapy Data at ELCC 2026 in Squamous and Non-squamous NSCLC across PD-L1 Expression Median PFS Median PFS, months (95% CI) NSQ NSCLC SQ NSCLC 100 Overall NSQ and 80 13.6 (8.3–NR
Slide 11: Broadening BioNTech's Coverage of Lung Cancer to Maximize Pipeline Potential
Broadening BioNTech’s Coverage of Lung Cancer to Maximize Pipeline Potential NSCLC SCLC Stage III Resectable 1L metastatic 2L+ metastatic 1L metastatic 2L+ metastatic Unresectable Incidence1 220K 65K 400K 230K 80K 35K Pumitamig2 Gotistobart3 ROSETTA PRESERVE-003 Pumitamig2 + LUNG-202 (sq) Pumitamig2
Slide 12: Gotistobart Phase Data Show Survival Benefit in CPI-Treated Squamous NSCLC
Gotistobart Phase 3 Data Show Survival Benefit in CPI-Treated Squamous NSCLC PRESERVE-003 trial stage 1 data at ELCC 2026: gotistobart1 reduces risk of death by 54% compared with docetaxel Overall Survival Gotistobart Docetaxel (n=45) (n=42) 100 Median OS, months NE 9.95 90 Gotistobart (95% CI) (9.3
Slide 13: BioNTech Key Tumor Focus Areas to Address Significant Unmet Medical Needs
BioNTech Key Tumor Focus Areas to Address Significant Unmet Medical Needs ADC Pumitamig1 IO mRNA Lung Breast Genitourinary Gastrointestinal Gynecologic Additional Tumors Leveraging novel combinations to maximize pipeline potential and elevate solid tumor treatment outcomes 1. Partnered with Bristol
Slide 14: Trastuzumab Pamirtecan: Encouraging Data in HER2-expressing EC
Trastuzumab Pamirtecan: Encouraging Data in HER2-expressing EC Data in Phase 1/2, Open-label, Dose-escalation and Expansion Study in HER2-expressing EC Confirmed Objective Response Rate by HER2 IHC Score1 Efficacy Measures HER2-expressing (Central Testing) Patient Population Prior ICI (n=73) All Pat
Slide 15: Development Focus of mRNA Cancer Immunotherapy iNeST and FixVac Portfolios
Development Focus of mRNA Cancer Immunotherapy iNeST and FixVac Portfolios Autogene cevumeran1 BNT113 BNT116 Adjuvant 1L Multiple settings CRC PDAC HPV16+ PD-L1 CPS ≥1 HNSCC NSCLC Phase 2 Phase 2 Phase 2/3 Phase 1 & 2 Monotherapy + Atezolizumab + mFOLFIRINOX + Pembrolizumab Mono & combo with IO & AD
Slide 16: Catalyst-Rich Year Ahead with Multiple Expected 2026 Milestones
Catalyst-Rich Year Ahead with Multiple Expected 2026 Milestones Program Trial Readout Phase Indication Single arm Phase 2 2L+ HER2-expressing endometrial cancer Trastuzumab pamirtecan3 Phase 35 interim analysis Chemo naïve HR+ HER2-low breast cancer Late-Stage Gotistobart2 Phase 35 interim analysis
Slide 17: Financial Performance
3 Financial Performance Ramón Zapata, Chief Financial Officer 17
Slide 18: First Quarter 2026 Financial Results
First Quarter 2026 Financial Results Q1 2026 Q1 2025 In € millions IFRS Results Adjusted Results2 IFRS Results Adjusted Results2 except per share data1 Revenues 118 118 183 183 Cost of sales (71) (71) (84) (84) Research and development expenses (557) (527) (526) (526) Sales, marketing, general and a
Slide 19: Reaffirming Full Year 2026 Financial Guidance
Reaffirming Full Year 2026 Financial Guidance1 In € millions FY 2026 non-IFRS Guidance Total Revenues 2,000 – 2,300 Adjusted R&D Expenses 2,200 – 2,500 Adjusted SG&A Expenses 700 – 800 • Competitive market dynamics in the United States • Begin managing transition away from multi-year contracts in Eu
Slide 20: Focused Capital Allocation Strategy for Sustainable Value Creation
Focused Capital Allocation Strategy for Sustainable Value Creation Focusing R&D Planning Share Manufacturing Investments Repurchase Program Footprint Consolidation Concentrate investments on advancing Plan to initiate share Enhance operational efficiency with BioNTech’s growing oncology pipeline rep
Slide 21: BioNTech Oncology Vision: Translating Science into Survival
BioNTech Oncology Vision: Translating Science into Survival Today 2026-2029 2030 Advanced Strategy, Drive Oncology Diversified Multi- Matured Pipeline Execution at Product Company and De-risked Scale and Speed Development Progress key Advance combination Build a diversified, programs into pivotal st
Slide 22: Thank you
Thank you
Slide 23: Appendix
__. Appendix BIONT=Cr
Slide 24: Reconciliation of IFRS to Adjusted Results – Q1 2026 & 2025 Financial Results
Reconciliation of IFRS to Adjusted Results – Q1 2026 & 2025 Financial Results Q1 2026 Q1 2025 In € millions IFRS Non-IFRS Adjusted IFRS Non-IFRS Adjusted except per share data1 Results Adjustments Results2 Results Adjustments Results2 Revenues 118 - 118 183 - 183 Cost of sales (71) - (71) (84) - (84
Slide 25: BioNTech's Oncology Pipeline
BioNTech’s Oncology Pipeline Phase 1 Phase 1/2 Phase 2 Phase 2/3 Phase 3 BNT116 BNT3214 Pumitamig1 Trastuzumab Autogene Pumitamig1 Pumitamig1 or Sacituzumab BNT113 BNT324/ Trastuzumab Adv. NSCLC Multiple solid tumors 1L adv./met. TNBC8 pamirtecan3 cevumeran2 2L ES-SCLC8 drozuntecan + 1L HPV16+ DB-13
Slide 26: BioNTech's Infectious Diseases Pipeline
BioNTech’s Infectious Diseases Pipeline Phase 1 Phase 1/2 Phase 2 Commercial BNT1631 BNT162 + BNT1612 BNT1665 BNT1622,3 HSV COVID-19 – Influenza combination Mpox COVID-19 BNT351 BNT1644 HIV Tuberculosis BNT165 Malaria Antibody mRNA Partnered with: 1. University of Pennsylvania; 2. Pfizer; 3. Fosun P
Slide 27: Abbreviation Directory
Abbreviation Directory nL nth line ESMO European Society for Medical Oncology mRNA Messenger ribonucleic acid AACR American Association for Cancer Research FAS APO-1 or CD95 MSS Microsatellite stability ADC Antibody-drug conjugate FixVac Fixed Antigen Vaccine NE Not evaluable for response adj. Adjuv